Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review

Abstract

Endometrial cancer, the most prevalent gynecological malignancy in developed countries, is experiencing a sustained rise in both its incidence and mortality rates, primarily attributed to extended life expectancy and lifestyle factors. Currently, the absence of precise diagnostic tools hampers the effective management of the expanding population of women at risk of developing this disease. Furthermore, patients diagnosed with endometrial cancer require precise risk stratification to align with optimal treatment planning. Metabolomics technology offers a unique insight into the molecular landscape of endometrial cancer, providing a promising approach to address these unmet needs. This comprehensive literature review initiates with an overview of metabolomic technologies and their intrinsic workflow components, aiming to establish a fundamental understanding for the readers. Subsequently, a detailed exploration of the existing body of research is undertaken with the objective of identifying metabolite biomarkers capable of enhancing current strategies for endometrial cancer diagnosis, prognosis, and recurrence monitoring. Metabolomics holds vast potential to revolutionize the management of endometrial cancer by providing accuracy and valuable insights into crucial aspects.

circRNAs in Endometrial Cancer—A Promising Biomarker: State of the Art

“…Moreover, insulin resistance and hyperglycemia lead to abnormalities in insulin-like growth factor (IGF-1) signaling and activation of the mammalian target of rapamycin (mTOR) through the pro-oncogenic PI3K/AKT/mTOR pathway, leading to the development of cancer [ 22 ]. Additionally, MS diseases are characterized by almost twice the incidence of EC [ 31 , 32 , 33 ].…”